Gregg Gilbert
Stock Analyst at Truist Securities
(2.80)
# 1,177
Out of 4,667 analysts
91
Total ratings
52.94%
Success rate
4.51%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $10.54 | +61.29% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $30.00 | +23.33% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $57.88 | +45.13% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly | Maintains: Buy | $430 → $525 | $753.41 | -30.32% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $12.63 | +2.93% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $16.86 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $97.44 | -4.56% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $10.18 | +371.51% | 2 | Feb 2, 2021 | |
| CHRS Coherus BioSciences | Initiates: Buy | $26 | $1.10 | +2,263.64% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $0.54 | +27,677.78% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $27.15 | +187.29% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $175.67 | -55.60% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $17.03 | +5.70% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $111.56 | - | 7 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $119.24 | +46.76% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $167.76 | -60.66% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $10.54
Upside: +61.29%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $30.00
Upside: +23.33%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $57.88
Upside: +45.13%
Eli Lilly
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $753.41
Upside: -30.32%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $12.63
Upside: +2.93%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $16.86
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $97.44
Upside: -4.56%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $10.18
Upside: +371.51%
Coherus BioSciences
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.10
Upside: +2,263.64%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $0.54
Upside: +27,677.78%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $27.15
Upside: +187.29%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $175.67
Upside: -55.60%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $17.03
Upside: +5.70%
Nov 20, 2017
Downgrades: Sell
Price Target: n/a
Current: $111.56
Upside: -
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $119.24
Upside: +46.76%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $167.76
Upside: -60.66%